



About SANOFI DIABETES

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions.

Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including blood glucose monitoring systems.

Aligned to the Sanofi Group's commitment to diabetes, Sanofi Diabetes India strives to become a true 360-degree partner for patients and healthcare professionals.

Through an integrated approach to diabetes management - comprehensive portfolio, patient support program 'Saath 7'; 'Made in India' reusable insulin pen AllStar™, public awareness drives and ongoing scientific initiatives - Sanofi endeavors to make a sustainable difference to the diabetes ecosystem in India - centered on patient needs.



Sanofi House, CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai, Mumbai 400 072, India

PREDICT SUMMIT

PREempting **D**iabetes
and **C**v complications
along with **T**ertiary care



An educational initiative by

SANOFI DIABETES



&

Association of Physician's of Ahmedabad





The Purpose

Diabetes and cardiovascular disease (CVD) pose significant threats to patients and major challenges to the medical community. Modifying type 2 diabetes and CVD risk factors offers the greatest potential for preventing or delaying both diseases and reducing associated morbidity and mortality.

In this meeting, the overlapping areas of diabetology and cardiology will be discussed through a case based discussion.

This expert perspective shall highlight important insights on the challenges of treating patients with type 2 diabetes mellitus (T2DM) and concomitant cardiovascular disease.

The ultimate aim of this unique initiative is to help clinicians identify at-risk patients, integrate evidence-based risk management strategies to target modifiable risk factors, and provide education to patients.



Agenda

Time	Topic	Speaker	Moderator
09:00 PM 09:15 PM	Context Setting		Dr. Deepak Dantara
09:15 PM 09:35 PM	Cardiovascular Safety of OADs Focus on Sulfonylureas Diabetologist's perspective	Dr. V. K. Abichandani	Dr. Jitendra Patel
09:35 PM 09:55 PM	Managing lipids in diabetes: Cardiologist's perspective	Dr. Hasit Joshi	Dr. N.D. Khimesara
09:55 PM 10:55 PM	New DPP4 Inhibitor (GEMIGLIPTIN) Launch	Dr. Navneet Shah	Dr. Raghu Satyanarayan

Date: 28 April, 2016

Time: 09.00 PM Onwards

Venue: RADISSON BLU

Ambawadi, Ahmedabad.

